Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

532729 RIP1 Kinase Inhibitor III - Calbiochem

A cell-permeable, potent, reversible inhibitor of RIP1 kinase (IC₅₀ = 63 nM in RIP fluorescence polarization assay).

RIP1 Kinase Inhibitor III - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 1-(4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, RIP1 Inhibitor III, Receptor-Interacting Protein 1 Inhibitor III

Primary Target: RIP1 Kinase
View Products on Sigmaaldrich.com
532729
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Specifications Table

Empirical Formula
C₂₀H₁₃F₄N₅O₂

Products

Catalog NumberPackaging Qty/Pack
5327290001 Glass bottle 10 mg
Description
OverviewA cell-permeable, orally available furopyrimidinyl-phenyl urea compound that acts as a potent and reversible inhibitor of receptor interacting protein 1 (RIP1) kinase (IC50 = 63 nM and 13 nM in RIP fluorescence polarization and ADP-Glo kinase assays, respectively). Binds to the ATP-binding pocket of RIP1 kinase with enzyme adopting a DLG-out inactive conformation. Shown to be moderately effective in inhibiting 25 other protein kinases in a screening of 300 kinases by radiolabeled assay, but only at high concentrations (~ 1 µM in the presence of 10 mM ATP). Blocks TNFα-induced necrotic cell death (IC50 = 250 nM in U937 cells) and protects mice from TNFα-induced hypothermic shock when injected 15 min. prior to i.v. administration of TNFα. Displays desirable pharmacokinetic properties with good systemic exposure following an oral dose (AUC= 14 mg/h/ml; Cmax = 1,100 ng/ml at 4 hours).

Please note that the molecular weight for this compound is batch-specific due to variable water content.
Catalogue Number532729
Brand Family Calbiochem®
Synonyms1-(4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, RIP1 Inhibitor III, Receptor-Interacting Protein 1 Inhibitor III
References
ReferencesHarris, P.A., et al. 2013. ACS Med. Chem. Lett. 4, 1238.
Product Information
FormLight orange powder
Hill FormulaC₂₀H₁₃F₄N₅O₂
Chemical formulaC₂₀H₁₃F₄N₅O₂
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary TargetRIP1 Kinase
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C).
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Identification Number
Catalog Number GTIN
53272900014055977281873

Documentation

RIP1 Kinase Inhibitor III - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Harris, P.A., et al. 2013. ACS Med. Chem. Lett. 4, 1238.

Technical Info

Title
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System
White Paper: Further considerations of antibody validation and usage.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-April-2015 JSW
Synonyms1-(4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, RIP1 Inhibitor III, Receptor-Interacting Protein 1 Inhibitor III
DescriptionA cell-permeable furopyrimidinyl-phenyl urea compound that potently inhibits RIP1 kinase activity (IC50 = 13 nM; [ATP] = 50 µM) by targeting RIPK1 ATP-binding pocket in its inactive DLG-out conformation (IC50 = 63 nM in competitive binding assays against 5 nM ATP-site ligand) without affecting RIPK2 or RIPK5 activity even at concentrations as high as 1 µM ([ATP] = 10 µM). Effectively prevents TNFα-induced necroptosis in Z-VAD(OMe)-FMK- (Cat. No. 627610) treated U937 cultures (EC50 = 250 nM) in vitro and is efficacious in protecting mice from body temperature loss (by 77%; 20 mg/kg p.o.) when administered 15 min prior to TNFα i.v. injection in vivo with good oral availability (plasma Cmax = 1100 ng/mL, Tmax = 4 h, AUC = 14 µg·h/mL; 2 mg/kg p.o.). Selectivity profiling in a 300-kinase panel shows significant inhibition against only 25 targets (IC50 <1 µM), notably RET, EPHA7, FLT3, EPHA6, HIPK4, DDR2, FMS, PDGFRa, and TrkC (% inhibition at 1 µM = 97%, 97%, 96%, 92%, 91%, 90%, 86%, 84%, 84%, respectively).
FormLight orange powder
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₂₀H₁₃F₄N₅O₂
Purity≥98% by HPLC
SolubilityDMSO (50 mg/ml). Use only fresh DMSO for reconstitution.
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C).
Toxicity Standard Handling
ReferencesHarris, P.A., et al. 2013. ACS Med. Chem. Lett. 4, 1238.